CN106132442A - 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 - Google Patents
血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 Download PDFInfo
- Publication number
- CN106132442A CN106132442A CN201580010172.XA CN201580010172A CN106132442A CN 106132442 A CN106132442 A CN 106132442A CN 201580010172 A CN201580010172 A CN 201580010172A CN 106132442 A CN106132442 A CN 106132442A
- Authority
- CN
- China
- Prior art keywords
- antibody
- method described
- dosage
- experimenter
- plasma kallikrein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Description
CDR | 氨基酸序列 |
重链CDR1 | HYIMM(SEQ ID NO:5) |
重链CDR2 | GIYSSGGITVYADSVKG(SEQ ID NO:6) |
重链CDR3 | RRIGVPRRDEFDI(SEQ ID NO:7) |
轻链CDR1 | RASQSISSWLA(SEQ ID NO:8) |
轻链CDR2 | KASTLES(SEQ ID NO:9) |
轻链CDR3 | QQYNTYWT(SEQ ID NO:10) |
Claims (74)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310760869.5A CN116585468A (zh) | 2014-01-21 | 2015-01-21 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929716P | 2014-01-21 | 2014-01-21 | |
US61/929,716 | 2014-01-21 | ||
US201461944361P | 2014-02-25 | 2014-02-25 | |
US61/944,361 | 2014-02-25 | ||
US201462021397P | 2014-07-07 | 2014-07-07 | |
US62/021,397 | 2014-07-07 | ||
PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310760869.5A Division CN116585468A (zh) | 2014-01-21 | 2015-01-21 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106132442A true CN106132442A (zh) | 2016-11-16 |
CN106132442B CN106132442B (zh) | 2023-07-14 |
Family
ID=53681890
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580010172.XA Active CN106132442B (zh) | 2014-01-21 | 2015-01-21 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
CN202310760869.5A Pending CN116585468A (zh) | 2014-01-21 | 2015-01-21 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310760869.5A Pending CN116585468A (zh) | 2014-01-21 | 2015-01-21 | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 |
Country Status (18)
Country | Link |
---|---|
US (2) | US11084884B2 (zh) |
EP (2) | EP3848057A1 (zh) |
JP (3) | JP6845012B2 (zh) |
KR (4) | KR20240049627A (zh) |
CN (2) | CN106132442B (zh) |
AU (2) | AU2015209481C1 (zh) |
BR (1) | BR112016016916B1 (zh) |
CA (1) | CA2937329C (zh) |
DK (1) | DK3096798T3 (zh) |
EA (1) | EA038532B1 (zh) |
ES (1) | ES2856076T3 (zh) |
IL (3) | IL246864B (zh) |
MX (2) | MX2016009428A (zh) |
NZ (2) | NZ723369A (zh) |
PL (1) | PL3096798T3 (zh) |
PT (1) | PT3096798T (zh) |
WO (1) | WO2015112578A1 (zh) |
ZA (2) | ZA201605342B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020238758A1 (zh) * | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2521568T (pt) | 2010-01-06 | 2018-10-26 | Dyax Corp | Proteínas de ligação à calicreína plasmática |
KR102169651B1 (ko) | 2011-01-06 | 2020-10-23 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
PL3096798T3 (pl) | 2014-01-21 | 2021-07-26 | Takeda Pharmaceutical Company Limited | Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
BR112017020864A2 (pt) * | 2015-03-30 | 2018-07-10 | Dyax Corp | inibidores de calicreína plasmática e usos dos mesmos para a prevenção de ataque de angioedema hereditário |
WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
EA201891002A1 (ru) * | 2015-10-19 | 2018-11-30 | Дайэкс Корп. | Иммунологический анализ для определения расщепленного высокомолекулярного кининогена |
CN108602893A (zh) * | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
CN109716138B (zh) * | 2016-09-16 | 2023-10-03 | 武田药品工业株式会社 | 用于接触活化系统相关的疾病的蛋白生物标记 |
EP3513188A1 (en) | 2016-09-16 | 2019-07-24 | Dyax Corp. | Rna biomarkers for hereditary angioedema |
BR112020007405A2 (pt) * | 2017-10-18 | 2020-12-08 | Regenxbio Inc. | Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
CN101801406A (zh) * | 2007-07-20 | 2010-08-11 | 基因塞斯投资有限公司 | 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶 |
CA3168591A1 (en) * | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
CN102307594A (zh) * | 2009-01-06 | 2012-01-04 | 戴埃克斯有限公司 | 用激肽释放酶抑制剂治疗粘膜炎 |
US20120201756A1 (en) * | 2011-01-06 | 2012-08-09 | Dyax Corp. | Plasma kallikrein binding proteins |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US5444156A (en) | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | METHOD FOR EVALUATING NEPHROTOXICITY. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
CN1292655C (zh) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
ES2372978T3 (es) | 2002-06-07 | 2012-01-30 | Dyax Corp. | Polipéptido con dominio de kunitz modificado. |
US20070253949A1 (en) | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
DK1854477T3 (en) | 2006-03-16 | 2016-11-28 | Dyax Corp | Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders |
KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
EP2195011A4 (en) | 2007-08-23 | 2010-12-01 | Genzyme Corp | TREATMENT WITH CALLICINE INHIBITORS |
CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
DK2946206T3 (en) | 2013-01-20 | 2019-04-15 | Dyax Corp | EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS |
EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
PL3096798T3 (pl) | 2014-01-21 | 2021-07-26 | Takeda Pharmaceutical Company Limited | Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego |
US10428158B2 (en) * | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
BR112017020864A2 (pt) | 2015-03-30 | 2018-07-10 | Dyax Corp | inibidores de calicreína plasmática e usos dos mesmos para a prevenção de ataque de angioedema hereditário |
CN108602893A (zh) | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
KR102464380B1 (ko) * | 2016-09-16 | 2022-11-07 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커 |
-
2015
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 EP EP20209536.0A patent/EP3848057A1/en active Pending
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Search and Examination
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en active Application Filing
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Application Filing
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active IP Right Grant
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 MX MX2016009428A patent/MX2016009428A/es unknown
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active IP Right Cessation
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US20210087293A1/en active Pending
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
CN101801406A (zh) * | 2007-07-20 | 2010-08-11 | 基因塞斯投资有限公司 | 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶 |
CN102307594A (zh) * | 2009-01-06 | 2012-01-04 | 戴埃克斯有限公司 | 用激肽释放酶抑制剂治疗粘膜炎 |
CA3168591A1 (en) * | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
US20120201756A1 (en) * | 2011-01-06 | 2012-08-09 | Dyax Corp. | Plasma kallikrein binding proteins |
Non-Patent Citations (2)
Title |
---|
江建雄;郑敏;: "遗传性血管性水肿的研究进展", 国际皮肤性病学杂志 * |
汤蕊;张宏誉;: "遗传性血管性水肿的治疗", 中华临床免疫和变态反应杂志 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
WO2020238758A1 (zh) * | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106132442A (zh) | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 | |
JP7309836B2 (ja) | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 | |
JP2020007354A (ja) | 抗血漿カリクレイン抗体 | |
JP7003354B2 (ja) | 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途 | |
JP7068160B2 (ja) | 第XIIa因子のモノクローナル抗体阻害剤 | |
TW202100561A (zh) | 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途 | |
CA3110689A1 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
NZ735659B2 (en) | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Rong Qiang Inventor after: Sexton Daniel J. Inventor after: Tenhoor Christopher Inventor after: A - Jon Kennison Inventor after: Ryan Forsythe Inventor after: Ryan Ilrobino Inventor after: Joseph Bidenkap Inventor after: Burt Adelman Inventor before: Rong Qiang Inventor before: Sexton Daniel J. Inventor before: Tenhoor Christopher Inventor before: A - Jon Kennison Inventor before: Ryan Forsythe Inventor before: Ryan Larobino Inventor before: Joseph Bidenkap Inventor before: Burt Adelman |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210611 Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd. Address before: Massachusetts, USA Applicant before: DYAX Corp. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |